로딩 중…
지수 로딩 중…
MYUNGMOON PHARM CO.,LTD
017180· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,283+0.00%
2026-09-18
Financials
Valuation Metrics
MYUNGMOON PHARM CO.,LTD's Market Cap is ₩436B. At end of 2025 it was ₩628B. Ranked #1864 of 2,421 in KR market (top 77%), #714 of 781 on KOSPI (top 91%), #197 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 85%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 43.56B KRW | KR#1,864/2,421 Sec#197/231 |
| Revenue | 199.82B KRW | KR#1,041/2,421 Sec#62/231 |
| Net Income | -2.57B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 300.16B KRW | KR#1,035/2,421 Sec#70/231 |
| Net Assets | 102.64B KRW | KR#1,394/2,421 Sec#111/231 |
| Employees | 297 | KR#794/2,421 Sec#68/231 |
| Value | ||
| P/B | 0.42x | KR#632/2,421 Sec#21/231 |
| P/S | 0.22x | KR#405/2,421 Sec#9/231 |
| EV/EBITDA | 116.00x | KR#1,506/2,421 Sec#101/231 |
| Profitability | ||
| ROE | -2.50% | KR#1,710/2,421 Sec#121/231 |
| ROA | -0.85% | KR#1,661/2,421 Sec#114/231 |
| Op. Margin | 0.76% | KR#1,525/2,421 Sec#106/231 |
| Revenue Growth | 4.75% | KR#1,212/2,421 Sec#118/231 |
| Earnings Growth | -156.83% | KR#1,213/2,421 Sec#78/231 |
| Financial Health | ||
| Debt Ratio | 192.44% | KR#2,082/2,421 Sec#217/231 |
| Total Debt | 157.21B KRW | KR#591/2,421 Sec#32/231 |
| Cash | 24.08B KRW | KR#1,134/2,421 Sec#76/231 |
| Current Ratio | 1.06x | KR#1,652/2,421 Sec#164/231 |
| Net Debt/EBITDA | 87.40x | KR#1,514/2,421 Sec#105/231 |
| Dividend | ||
| Div. Growth | 18.83% | KR#471/2,421 Sec#25/231 |
| Performance | ||
| 1Y Return | -25.84% | KR#1,420/2,421 Sec#103/231 |
| 1M Return | 7.27% | KR#605/2,421 Sec#42/231 |
| From 52W High | -37.57% | KR#812/2,421 Sec#55/231 |
| 1Y MDD | -45.66% | KR#798/2,421 Sec#64/231 |
| Trading | ||
| Volume | 84,670 shares | KR#862/2,421 Sec#82/231 |
| Trading Value | 109.2M KRW | KR#1,509/2,421 Sec#151/231 |
| Foreign Own. | 2.20% | KR#1,556/2,421 Sec#147/231 |
| Per Share | ||
| EPS | -76 KRW | KR—/2,421 Sec—/231 |
| BPS | 3,023 KRW | KR#1,857/2,421 Sec#140/231 |
Company Info
동사는 1983년 설립된 제약회사로, 2018년 제2공장을 신축하고, 2024년 종속회사 명문바이오가 GMP 인증을 획득하여 의약품 공급 및 매출 성장 기반을 마련함. 의약품부문에서 경피흡수제형 패취제와 고혈압, 당뇨, 항암제 등을 연구 및 출시하고 있으며, 서비스부문에서는 골프클럽을 운영하고 있음. 인구고령화에 따른 의약품 수요 증가와 난치성 질환 치료제 시장 성장에 대응하여 매출액의 약 2.49%를 연구 개발에 투자하고 있음. 명문제약는 1983년에 설립되었으며 경기도 화성시에 본사를 두고 있습니다.